Skip to main content
Fig. 7 | Experimental Hematology & Oncology

Fig. 7

From: Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia

Fig. 7

HDAC2 plays as an interactor with c-Myc and an indicator for AML prognosis. (A) Co-Immunoprecipitation analysis for c-Myc, HDAC1, and HDAC2 in U937 and THP-1 cells. (B) The elevated expression levels of HDAC2 in AML versus normal donors. The overall survival curves of HDAC2high or HDAC2low groups in AML patients cohort (C) and de novo cohort (D). The relapse-free survival curves of HDAC2high or HDAC2low groups in AML patients cohort (E). *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us